EGFR and non-small cell lung carcinoma: Mechanistic analyses revealed that the combination therapy inhibited phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 and promoted degradation of anti-apoptotic protein myeloid cell leukemia-1, leading to enhanced induction of apoptosis.61 These findings support further clinical evaluation of honokiol and its derivatives as adjuvants to overcome osimertinib resistance in EGFR-mutant NSCLC.